Cartagenia raises €4.25m from Capricorn et al.

Backers include Leuven-based Capricorn Ventures via Capricorn ICT Arkiv, a digital healthcare vehicle; Flemish investment company PMV; and the University of Leuven venture fund, the Gemma Frisius Fund.

The fresh funding will be used to commercialise the company's platform in key markets including North America and Europe. The firm will also widen its product portfolio to branch into oncology and reproductive health.

Previous funding
In 2011, Cartagenia raised €2.2m. PMV, Gemma Frisius Fund and the company's founders provided half of the funding, with the remaining capital committed by Euronext-listed investor Quest For Growth.

Company
Founded in 2008 and based in Leuven, Cartagenia provides a software-as-a-service to support lab reporting and data sharing for clinical genetic testing applications. Its platform is used in array testing in constitutional and rare disease, prenatal diagnosis and screening, and germline and somatic oncology assays.

Cartagenia counts more than 120 labs and clinics in North America, Europe and Australia among its user base.

People
Herman Verrelst is CEO of Cartagenia.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Technology
• Expansion
• Belgium